Preventing the Effects of Climate Change: EliTerra®, a Technological Platform Dedicated to Biosolutions That Reduce the Water Needs of Field Crops
Elicit Plant announces the acceleration of its scientific developments and its product roadmap by presenting the one and only technological platform that offers biosolutions to help prevent climatic risks for field crops by reducing their water consumption by up to 20%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005298/en/
On the occasion of its participation in the ChangeNOW Summit, the event for solutions for the planet that takes place from May 25 to 27, 2023 in Paris, Elicit Plant unveils EliTerra®, its technological platform and associated products that allow crops to adapt to climate change, particularly to drought. This is a world first that will boost the marketing of new Elicit Plant BioSolutions with a favorable environmental profile, following on from the success of its first product, BEST-a, which enables corn to consume up to 20% less water.
"This type of solution is particularly expected by the agricultural sector at a global level, in the context of climate change," adds Francesc Llaurado of Lainco Agro, an agronomist expert in the Mediterranean basin, "As a Spaniard, I am particularly affected by what is happening in my country, but it is the entire global agricultural sector that must consider adapting practices to the agro-ecological transition and better preservation of resources and agricultural yields with the rapid adoption of innovative solutions to counteract the impact of climate change, especially on field crops. »
The EliTerra® technology platform is the result of Elicit Plant's research on phytosterols, which has shown that these plant sterols are essential for stress resistance in row crops (corn, wheat, soybeans, etc.). The process of discovery and validation by Elicit Plant's laboratories and its scientific partners has enabled the identification of new formulations composed of different phytosterols to specifically and effectively fight against the impact of climate change on several major crops. The resulting product roadmap will be announced in the various countries targeted in Europe, Brazil, and North America where marketing authorization applications are underway.
Benoit Poinssot, Research Professor at the UMR Agroecology (INRAE, University of Burgundy, Institut Agro Dijon), explains: "There is not one but many phytosterols. In nature, there are more than 200 of them, each of which is stress-specific and species-specific. Phytosterols are therefore not a universal generic solution and their level of performance on crops depends on their diversity but also on their combination and of course on the formulation. The EliTerra® platform therefore offers very significant potential for product development. »
These natural and sustainable solutions are part of the dynamic of helping agriculture meet the challenge of feeding the world's population despite the effects of climate change.
Philippe Merle, Director of the Agriculture Division at the Océalia cooperative (New Aquitaine), says that "the impact of climate change on row crops is very strongly perceived by our members and the good performance of BEST-a Maize has encouraged very rapid adoption in our territory with more than 30% of our areas treated for water stress with this product in the second year. In 2023, we are testing two new prototypes of the EliTerra® Platform on wheat, barley and soybeans, with the aim of marketing them next season, and we have high ambitions for these new products. »
What are phytosterols?
Phytosterols are plant lipids. While animals only synthesize one cholesterol, plants produce a large number of them, which are also components of cell membranes. These molecules are part of the primary metabolism of living organisms and are therefore essential to their survival. Their presence in the membranes plays a central role in the regulation of their fluidity and thus their permeability. It is through these mechanisms that the 'signal' molecules carry information for a stimulation of the growth of the plant and/or an adapted response of the plants to the changes of the environmental conditions.
About Elicit Plant:
Elicit Plant is an agri-biotech company whose ambition is to become the champion of the ecological transition for agriculture and respond to the global challenges of the impact of climate change on row crops. EliTerra®, Elicit Plant's proprietary technology, is based on the exogenous contribution of phytosterols, a set of molecules of plant origin, which increases the resistance of plants to stress by eliciting their natural defenses. Large-scale field trials - more than 500 trials on 3 continents - have demonstrated that the biosolutions from the Eliterra® Platform are the only ones offering farmers a regular and sufficient return on investment for use on field crops, with an average yield gain of 12%. In 2022, Elicit Plant began marketing its BEST-a product line in France, particularly for corn crops, and has obtained marketing authorizations for Ukraine, Brazil and Europe. For more information: www.elicit-plant.com
More pictures on www.elicit-plant.com/en/espace-presse
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release
Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230929518869/en/ Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K
The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release
For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom